# Ellen Hukkelhoven

> Ellen Hukkelhoven is a Series B investor at Perceptive Advisors backing Health Care. See 9 investments, check sizes, portfolio and contact details. Updated…

- Type: Angel Investor
- Fund: [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors)
- Location: New York, United States
- Total investments: 9
- Last investment: Feb 2024
- Lead investor: 56%
- Last updated: Oct 2026
- LinkedIn: https://www.linkedin.com/in/ellen-hukkelhoven-20129821/
- X (Twitter): https://x.com/hukkelle
- Facebook: https://www.facebook.com/ellen.hukkelhoven/

Ellen Hukkelhoven is a Series B investor at Perceptive Advisors in New York focused on Health Care and Medical. Ellen Hukkelhoven is based out of New York, New York, and is the head of investment research of Perceptive Advisors. Ellen previously worked at The Daily Princetonian as a business manager. Ellen Hukkelhoven attended Princeton University.

## Contacts

5 contacts available for Ellen Hukkelhoven: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/ellen-hukkelhoven?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 22% |
| Medical | 1 | 11% |
| Women's | 1 | 11% |
| Oncology | 1 | 11% |
| Wellness | 1 | 11% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 22% |
| Series C | 2 | 22% |
| Series A | 1 | 11% |
| Series D | 1 | 11% |
| Series E | 1 | 11% |

7 stages tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Freenome | Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening. | $254M | Series E | Feb 15, 2024 | https://www.freenome.com/ |
| Kindbody | Kindbody operates a health and tech company intended to offer fertility services and treatments for the modern woman. It offers a full range of services including intrauterine insemination, in-vitro fertilization, donor support, egg freezing, and embryo freezing, enabling women to improve their overall health and wellbeing. | $100M | Debt Financing | Mar 02, 2023 | https://www.kindbody.com/ |
| Freenome | Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening. | $300M | Series D | Dec 07, 2021 | https://www.freenome.com/ |
| Kindbody | Kindbody operates a health and tech company intended to offer fertility services and treatments for the modern woman. It offers a full range of services including intrauterine insemination, in-vitro fertilization, donor support, egg freezing, and embryo freezing, enabling women to improve their overall health and wellbeing. | $62M | Series C | Jun 25, 2021 | https://www.kindbody.com/ |
| Freenome | Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening. | $270M | Series C | Aug 26, 2020 | https://www.freenome.com/ |
| Kindbody | Kindbody operates a health and tech company intended to offer fertility services and treatments for the modern woman. It offers a full range of services including intrauterine insemination, in-vitro fertilization, donor support, egg freezing, and embryo freezing, enabling women to improve their overall health and wellbeing. | $32M | Series B | Jul 08, 2020 | https://www.kindbody.com/ |
| Freenome | Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening. | $160M | Series B | Jul 24, 2019 | https://www.freenome.com/ |
| Kindbody | Kindbody operates a health and tech company intended to offer fertility services and treatments for the modern woman. It offers a full range of services including intrauterine insemination, in-vitro fertilization, donor support, egg freezing, and embryo freezing, enabling women to improve their overall health and wellbeing. | $15M | Series A | Apr 16, 2019 | https://www.kindbody.com/ |

8 of 9 investments shown.

## Co-investors
- [S32](https://shizune.co/investors/profile/section-32) — VC Fund, 8 deals together
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 5 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 5 deals together
- [T. Rowe Price](https://shizune.co/investors/profile/t-rowe-price) — VC Fund, 5 deals together
- [Bain Capital Life Sciences](https://shizune.co/investors/profile/bain-capital-life-sciences) — VC Fund, 4 deals together
- [Rock Springs Capital](https://shizune.co/investors/profile/rock-springs-capital) — VC Fund, 4 deals together

## About Perceptive Advisors

VC Fund · New York, United States

Perceptive Advisors is a privately owned hedge fund sponsor. The firm invests in the public equity markets across the globe. It employs a long/short equity strategy as a hedging technique while investing. The firm typically invests in the biotechnology and life sciences sectors to make its investments. Perceptive Advisors is based in New York,New York.

5 contacts available at Perceptive Advisors.

| Name | Title | Profile |
| --- | --- | --- |
| Ellen Hukkelhoven | Head of Investment Research | https://shizune.co/investors/profile/ellen-hukkelhoven |
| Fred Callori | Managing Director of Venture | https://shizune.co/investors/profile/fred-callori |
| Joseph Edelman | CEO & Founder | https://shizune.co/investors/profile/joseph-edelman |
| Orly Mishan | Managing Director, Perceptive Discovery | https://shizune.co/investors/profile/orly-mishan |
| Adam Stone | Chief Investment Officer | https://shizune.co/investors/profile/adam-stone-5 |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Ellen Hukkelhoven invest in?

Ellen Hukkelhoven invests primarily in Health Care, Medical and Women's startups, most often at Series B and Series C stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Ellen Hukkelhoven?

Public channels for Ellen Hukkelhoven include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Ellen Hukkelhoven last invest?

The most recent investment recorded for Ellen Hukkelhoven closed in Feb 2024. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co